Monogram Biosciences, part of LabCorp's Specialty Testing Group, is a market leader in HIV-1 drug susceptibility testing.
Monogram Biosciences, part of LabCorp's Specialty Testing Group, is a market leader in HIV-1 drug susceptibility testing. Our fully CLIA/CAP accredited clinical reference laboratory provides testing for clinical patient management and drug/vaccine development related to HIV, HCV, Oncology, and Influenza. Monogram Biosciences develops novel antiviral resistance assays for HIV and hepatitis. These include Trofile® for HIV-1 patients considering CCR5 antagonist therapy and HCV GenoSure® NS3/4A to assess drug resistance for HCV protease inhibitors. Monogram Biosciences, founded in November 1995, became part of the LabCorp Specialty Testing Group in August 2009.
Mission: To improve healthcare by advancing individualized medicine through the discovery and commercialization of innovative products that guide and improve the treatment of serious viral infections and cancer
December 1st is #WorldAIDSDay. This year's theme: "Leadership. Commitment. Impact."
#OnThisDate in 1991, NBA Hall of Famer and Los Angeles Lakers star Earvin “Magic” Johnson announced that he was HIV-positive.
During a press conference in 1991 basketball legend Magic Johnson announces he has HIV and is leaving the NBA.
[10/26/16] In October of 1986, U.S. Surgeon General, C. Everett Koop, issues the Surgeon General’s Report on AIDS. The report urges parents and schools to start frank, open discussions about AIDS and urges education and condom use. #TBT
Join Monogram Biosciences' Chief Scientific Officer Christos Petropoulos as he discusses recent technological advances that may reinvigorate HIV vaccine development. Register here:
xtalks.com Join Christos Petropoulos, Chief Scientific Officer, Monogram Biosciences and Vice President, LabCorp, as he discusses recent technological advances that have illuminated promising new approaches for immunogen design, vaccine delivery and vaccination.
Today is National Latino AIDS Awareness Day in the U.S., first recognized in 2003. #OnThisDate
aids.gov October 15 is National Latino AIDS Awareness Day.
#OnThisDate in 1987, the AIDS Memorial Quilt was displayed for the first time on the National Mall in Washington, D.C., during the National March on Washington for Lesbian and Gay Rights.
aidsquilt.org In June of 1987, a small group of strangers gathered in a San Francisco storefront with a goal to create a memorial for those who had died of AIDS.
In October 2007, the U.S. Centers for Disease Control and Prevention (CDC) launch Prevention IS Care (PIC), a social marketing campaign designed for healthcare providers who deliver care to people living with HIV #TBT
cdc.gov Prevention IS Care therefore includes tools for medical care providers to use on a daily basis with those patients who are living with HIV.
In the News: Temple University researchers successfully eliminate HIV-1 virus from the genome of human T-cells using the specialized gene editing system.
news.temple.edu Researchers from the Lewis Katz School of Medicine at Temple University make another landmark discovery in the fight against HIV and AIDS.
Today is National Gay Men’s HIV/AIDS Awareness Day, first recognized #OnThisDate in 2008.
aids.gov In 2008 the National Association of People with AIDS (NAPWA) launched this observance day to recognize the disproportionate impact of the epidemic on gay men.
Monogram Biosciences' Chief Scientific Officer Christos Petropoulos, PhD, was a guest speaker at the #CDC Hepatitis C Diagnostic Summit held earlier this month in Atlanta, where he was part of a panel discussion regarding testing practices, platforms, and challenges in implementing the CDC’s updated hepatitis C testing guidelines:
cdc.gov Tanya Applegate, PhD Francisco Averhoff, MD Adrian Di Bisceglie, MD Bernie Branson, MD Michael Chapko, PhD George Dawson, PhD Claudia Denkinger, MD Brian Edlin, MD Jeffrey Engel, MD Michael Fried, MD Anne Gaynor, PhD Lilia Ganova-Raeva, PhD Fengxiang Gao, PhD Camila Graham, MD Susan Hariri, PhD Scot...
How many people are diagnosed with HIV each year in the United States? Find the answer to this and more #HIV #AIDS statistics:
cdc.gov Start here to learn the basics of HIV and AIDS and learn how to take steps to prevent transmission and protect yourself from HIV.
Learn the basics about #HIV and #AIDS:
cdc.gov Start here to learn the basics of HIV and AIDS and learn how to take steps to prevent transmission and protect yourself from HIV.
A great infographic from HealthHIV on The State of #HCV in the United States. Visit http://www.healthhiv.org/ for more from HealthHIV.
Monogram Bioscience's Dr. Jackie Reeves presented research on genotypic and phenotypic resistance for HCV testing at EASL's #ILC2016 in Barcelona, Spain:
livertree.easl.eu EASL LiverTree™. Reeves J. Apr 14 2016; 126560;
[08/04/16] In August 1987, the U.S. Centers for Disease Control and Prevention (CDC) hold the first National Conference on HIV and Communities of Color in New York. #TBT
[07/28/16] The Presidential Advisory Council on HIV/AIDS (PACHA), established by former President Bill Clinton, meets for the first time on this date, July 28, 1995. #TBT
[07/25/16] #OnThisDate in 1983, San Francisco General Hospital opens the first dedicated AIDS ward in the United States.
[07/23/16] One year ago today, the U.S. Food and Drug Administration approved the first diagnostic test that differentiates between different types of HIV infections (HIV-1 and HIV-2). The test can also differentiate between acute and established HIV infections. #OnThisDate http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455813.htm
#OnThisDate in 2010, the Obama Administration releases the first comprehensive National HIV/AIDS Strategy for the United States.
aids.gov The Strategy and the action steps it contains are the result of broad-based engagement with Federal and community partners.
[06/25/16] #OnThisDate in 1998, the U.S. Supreme Court ruled that the Americans with Disabilities Act (ADA) covers those in earlier stages of HIV disease, not just those who have developed AIDS. http://1.usa.gov/1Zs9xwY
[06/16/16] In June 1995, the U.S. Food and Drug Administration (FDA) approves the first protease inhibitor. This ushers in a new era of highly active antiretroviral therapy (HAART). #TBT #HIV http://1.usa.gov/1Zs9xwY
June 8 is Caribbean American HIV/AIDS Awareness Day. Learn more here:
Monogram is one of a select number of collaborators in the Institute for #HIVCure Research, made possible by a $20 million grant from the Foundation for AIDS Research (amfAR).
ucsf.edu In a bid to end the worst epidemic in modern times, the Foundation for AIDS Research (amfAR) is funding an ambitious effort based in San Francisco to eliminate the human immunodeficiency virus (HIV) from those who are infected.
New AASLD Guidance includes recommendations for #NS5Aresistance testing for new #HCV direct-acting antiviral agents:
hcvguidelines.org This section provides guidance on monitoring patients with chronic hepatitis C who are starting treatment, are on treatment, or have completed treatment. The section is divided into three parts: pretreatment and on-treatment monitoring, posttreatment follow-up for persons in whom treatment has faile…
Almost-certain case of pre-exposure prophylaxis (#PrEP) failure due to drug resistance reported at #CROI2016:
aidsmap.com Based on probabilities, this is the first documented case of the failure of Truvada PrEP…
“As a recognized leader and innovator in state of the art, cell-based and molecular diagnostic assays that inform effective, individualized treatment of HIV-1 infection, Monogram is exploring how we can best apply our technical experience and expertise to the development and evaluation of HIV curative therapies.
We are pursuing these efforts with the support of two exploratory research grants awarded to Monogram from the NIH/NIAID, along with collaborations that leverage our long-standing and productive scientific relationships with industry, government and academic institutions and investigators”
Christos J Petropoulos, PhD, Chief Scientific Officer, Monogram Biosciences #HIVCure #Quotes
Our recent case study published in the Journal of the International Association of Providers of AIDS Care highlights the relevance and importance of baseline resistance testing. The study profiles the first case of a patient who contracted 5-class drug resistant virus, but was successfully treated based on selection of an active ARV drug regimen.
ncbi.nlm.nih.gov Transmitted HIV-1 exhibiting reduced susceptibility to protease and reverse transcriptase inhibitors is well documented but limited for integrase inhibitors and enfuvirtide.
We are proud of Monogram scientists Wei Huang, Joe Volpe and Christos Petropoulos, who contributed and/or authored four presentations at #CROI2016. Check out their work on the conference’s website:
croiconference.org The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS
#HIV has a number of key steps in its lifecycle that make for effective drug targets. Monogram Biosciences has developed diagnostics for many of these key intervention points and has been a valuable partner for companies developing drug interventions.
[02/23/16] Monogram Biosciences’ Joseph Volpe was a featured presenter at #CROI2016 discussing HIV drug resistance and transmission. Check out his poster presentation, “An Informatics Approach to Predicting Rates of Transmitted HIV-1 Drug Resistance."
Monogram Biosciences is proud to be a part of #CROI2016 in Boston this month, where we will present seven years’ worth of data on transmitted drug resistance. Will you be there?
croiconference.org The annual Conference on Retroviruses and Opportunistic Infections (CROI) brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infecti…
Monogram technology, including its GenoSure and PhenoSenseGT assays, played an important role in identifying the probable source of a multidrug-resistant dual-tropic HIV-1 infection that resulted in a New York City public health scare. Read more about the case in the Journal of Infectious Diseases.
Genotypic, recombination, and phylogenetic analyses suggest CT02 became superinfected by CT01 with subsequent production of a recombinant panresistant HIV-1.
#TBT On this date in 2005, New York City officials issued a public health alert regarding a highly multidrug-resistant dual-tropic HIV-1 infection. Monogram was among the labs that helped not only identify the strain, but also establish a baseline resistance profile.
ncbi.nlm.nih.gov Rapid progression to AIDS after acute HIV-1 infection, though uncommon, has been noted, as has the transmission of multidrug resistant viruses. Here, we describe a patient in whom these two factors arose concomitantly and assess the effects.
Monogram will be at #CROI2016! We hope to see you there!
croiconference.org CROI is a global model of collaborative science and the premier international venue for bridging basic and clinical investigation to clinical practice in the field of HIV and related viruses.
Genotyping and phenotyping provide complementary information. This is why Monogram offers combination tests—to give the greatest amount of information about a patient’s virus. The genotype provides information about key mutations, and the phenotype provides observations of viral susceptibility to the drugs. #NoOnePatientIsAlike
Genotyping vs. Phenotyping: What’s the Difference? Genotyping provides a prediction of drug susceptibility using Monogram’s proprietary database of HIV-1 genotype-phenotype results. Phenotyping is a direct observation of how well drugs inhibit the virus by exposing a sample of an individual’s HIV to antiretroviral drugs. Learn more: http://bit.ly/1X7D4tq
[01/13/16] TECHNICAL REVIEW DOWNLOAD: Detection of acute infections using the fourth-generation HIV screening assay provides an opportunity for early therapeutic intervention and the potential to affect transmission rates: http://bit.ly/4thGenTechReview
During #ICAAC in San Diego, Monogram Biosciences researchers discussed new data on trends of transmitted drug resistance mutations in HIV-infected patients:
Did You Know: Monogram is actively expanding its portfolio of products to assist with drug development and the treatment of patients infected with hepatitis C virus:
monogrambio.com Monogram is proud to apply our expertise in virology and drug resistance testing to the hepatitis C virus (HCV). We are actively developing a new portfolio of products to assist with drug development and the treatment of patients infected with HCV. We also offer an extensive line of diagnostic tests…
Did you know: HCV genotype/subtype (1a, 1b, 2, 3, 4, 5, or 6) may impact patient treatment decisions. In the United States, the most common HCV genotype is genotype 1a (60.3%) and genotype 1b (16.7%) #NoOnePatientIsAlike
Thirty drugs have been approved for HIV since the virus was discovered in 1983. See the evolutionary timeline for new drugs and related testing Monogram has developed to support treatment decisions at http://www.monogrambio.com/hiv-tests.
The need for resistance testing expands to treating patients with Hepatitis C virus
hcvguidelines.org UPDATED AASLD-IDSA RECOMMENDATIONS
Monogram is proud to apply our expertise in virology and drug resistance testing to the hepatitis C virus (HCV).
hcvguidelines.org AASLD-IDSA recommendations for testing, treatment, management
HIV tropism results can help develop a personalized treatment plan for patients. Appropriate use of a CCR5 antagonist, such as maraviroc, requires that an HIV tropism test be performed before initiation of therapy. #NoOnePatientIsAlike
Monogram Biosciences presented new data on HIV-1 transmission in the California AIDS Healthcare Foundation Network at #ICAAC in San Diego:
Founded by Jordan Newmark, M.D. in November of 2011
Tips on Chronic Pain, Meditation, Rehabilitation, and Peak Health for 2020
eos migraine specializes in the surgical treatment of migraines.
The Kairos Moment in Healthcare Kairos (Greek): “A moment of rare opportunity; an opening for those who can adapt to changing circumstances.”
Genome Medical is a nationwide genomics medical practice providing expert genetic services to improve health, diagnose and treat disease.
Amplify Health believes the most important relationship in healthcare is between the patient and their primary care physician.
Helping spread the message of recovery in the SF Bay Area. www.bayarearehab.com
Augmedix provides dedicated clinical support and medical documentation so clinicians can focus on what matters most: patient care.
Discover the symptoms, causes, diagnosis and treatments for hirsutism, a condition that causes an excessive amount of hair to grow on women's faces and bodies http://hirsutismtreatment.net/
www.sfmidwifery.com german trained family midwife offering 25+ years of service. Complimentary interviews. Home birth comprehensive midwifery/coaching services for hospital births. Complete pre and postnatal care. birth and parenting mindfulness classes